Search

Displaying results 3311 - 3320 of 5302 in total
  1. Drug

    Arbaclofen Placarbil

    go.drugbank.com/drugs/DB08892
    Investigational

    It was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties.

  2. Drug

    DADLE

    go.drugbank.com/drugs/DB08856
    Experimental

    It can cause transient depression of mean arterial blood pressure and heart rate.

  3. Drug

    Raxibacumab

    go.drugbank.com/drugs/DB08902
    ApprovedInvestigational

    Raxibacumab is a human IgG1λ monoclonal antibody that binds the protective antigen (PA) component of B. anthracis toxin. Raxibacumab has a molecular weight of approximately 146 kilodaltons. Raxibacumab is produced by recombinant DNA tech...

  4. Drug

    Picosulfuric acid

    go.drugbank.com/drugs/DB09268
    ApprovedInvestigational

    The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years.[A33322]

  5. Drug

    Leptin

    go.drugbank.com/drugs/DB05098
    Investigational

    Although leptin is a circulating signal that reduces appetite, in general, obese people have an unusually high circulating concentration of leptin.

  6. Drug

    Bitolterol

    go.drugbank.com/drugs/DB00901
    ApprovedWithdrawn

    Bitolterol mesylate was used to treat bronchospasms in asthma and COPD. It is a beta-2-adrenergic receptor agonist. Bitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001.

  7. Drug

    Deslanoside

    go.drugbank.com/drugs/DB01078
    Approved

    Deacetyllanatoside C. A cardiotonic glycoside from the leaves of Digitalis lanata.

  8. Drug

    Fluticasone

    go.drugbank.com/drugs/DB13867
    ApprovedInvestigationalWithdrawn

    Fluticasone is a synthetic glucocorticoid available as 2 esters, DB08906 and DB00588 [FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications [FDA Label]. DB00588 was ...

  9. Drug

    CNS-5161

    go.drugbank.com/drugs/DB05824
    Experimental

    CNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.

  10. Drug

    Ceftobiprole medocaril

    go.drugbank.com/drugs/DB14733
    Approved

    The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion of ceftobiprole medocaril in February 2010, recommending the refusal of its marketing authorization in the European